Highgrove Publishing is continuing to promote and publish what it calls The European Medicines Evaluation Annual 1996, which the European Medicines Evaluation Agency stresses has nothing to do with it.
The agency is investigating the possible abuse of the name "EMEA," and says it reserves the right to take legal action on the matter. The EMEA also notes that information concerning its directory, membership, press releases, general outline of the European drug registration system and other information on the agency's work, is readily available free of charge to the general public, and can be obtained on the Internet or from national authorities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze